Holen Sie sich die Stockscreener-App
1,041.29
0.28%
2.89
Vorhandelsmarkt:
1039.00
-2.29
-0.22%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
Eli Lilly Faces Regulatory Delay as Key Drug Approval Pushed to 2026 - AD HOC NEWS
What Happened to Viking Therapeutics in 2025, And Is it a Buy for 2026? - The Motley Fool
Abivax CEO Dismisses Rumors of Eli Lilly (LLY) Takeover as ‘Noise’ - TipRanks
Eli Lilly (LLY) Denies Acquisition Talks with Abivax (ABVX) - GuruFocus
Bernstein reiterates Outperform rating on Eli Lilly stock with $1,300 price target - Investing.com
New GCGR agonists disclosed in Eli Lilly patent - BioWorld MedTech
Abivax CEO dismisses 'noise' around rumored Eli Lilly bid - Reuters
Guggenheim Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $1,161 - 富途资讯
Eli Lilly (LLY) Receives FDA Breakthrough Designation for New Ca - GuruFocus
Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer - Eli Lilly
FDA grants Breakthrough status to drug for hard-to-treat ovarian cancer - Stock Titan
Abivax CEO dismisses ’noise’ around rumored Eli Lilly bid By Reuters - Investing.com
Morgan Stanley reiterates Overweight rating on Eli Lilly stock ahead of obesity trial data By Investing.com - Investing.com South Africa
Morgan Stanley reiterates Overweight rating on Eli Lilly stock ahead of obesity trial data - Investing.com
Eli Lilly (LLY) Faces Competition from Structure Therapeutics' P - GuruFocus
Eli Lilly Faces Headwinds Amid Regulatory Delay and Legal Challenge - AD HOC NEWS
Silicon Meets Science: NVIDIA and Eli Lilly Launch $1 Billion AI Lab to Engineer the Future of Medicine - FinancialContent
The Best Healthcare Stocks to Buy With $5,000 in 2026 and Hold Forever - Finviz
Compounder sues Lilly and Novo for suppressing GLP-1RA competition - Pharmaceutical Technology
Eli Lilly's Taltz and Zepbound Combo Delivers Superior Results in Landmark Psoriatic Arthritis Trial - Finviz
Eli Lilly price tries to recoup some lossesForecast today19-01-2026 - Economies.com
Eli Lilly's (NYSE:LLY) Five-year Total Shareholder Returns Outpace the Underlying Earnings Growth - 富途资讯
Eli Lilly vs. Novo Nordisk: Which Stock Offers More Upside? - CoinCentral
OpenAI Backed Chai Discovery Partners With Eli Lilly to Accelerate Biologics Discovery - AIM Media House
Chai Discovery Strikes Eli Lilly AI Drug Deal - findarticles.com
Eli Lilly's Weight Loss Portfolio Generates $10 Billion in Quarterly Revenue - Intellectia AI
Prediction: 2026 Will Be the Year of Eli Lilly - The Motley Fool
Eli Lilly Faces Regulatory Delay for Weight-Loss Drug Candidate - AD HOC NEWS
What Eli Lilly (LLY)'s NVIDIA AI Lab And Obesity Data Reveal About Its Obesity Leadership Narrative - Yahoo Finance
The Truth About Eli Lilly (NYSEreplacing with LPLA): Why Everyone Is Suddenly Watching This Stock - AD HOC NEWS
Notable healthcare headlines for the week: Eli Lilly, UnitedHealth, and Boston Scientific in focus - MSN
Could Acquiring Ventyx Biosciences Send Eli Lilly Stock Soaring in 2026? - The Motley Fool
Eli Lilly Shares Face Pressure Following Regulatory Setback - AD HOC NEWS
Eli Lilly stock price in focus as FDA slips obesity pill deadline — what to watch in LLY next week - TechStock²
This pharmaceutical executive has Trump's ear - Politico
BMO Reaffirms Eli Lilly and Company (LLY) as an Obesity Market Leader - Finviz
Eli Lilly’s Strategic Moves in the Weight-Loss Drug Arena - AD HOC NEWS
Eli Lilly Partners with Nvidia to Invest $1 Billion in AI Drug Discovery - Intellectia AI
Eli Lilly: A Strong Player in the Pharmaceutical Arena - The Motley Fool
Eli Lilly stock: FDA pushes orforglipron decision to April 10 as lawsuit adds another overhang - TechStock²
Stock Quote & Chart | Eli Lilly and Company - Eli Lilly
Chai Discovery and Eli Lilly Partner to Accelerate AI-Driven Drug Development - Букви
From OpenAI’s offices to a deal with Eli Lilly — how Chai Discovery became one of the flashiest names in AI drug development - TechCrunch
Eli Lilly vs. Novo Nordisk: Which Is the Better Stock Buy? - The Motley Fool
Novo's Wegovy pill makes encouraging start in weight-loss race vs Lilly - Reuters
LLY Stock Falls After FDA Reportedly Delays Obesity Drug Ruling - Yahoo Finance
Nvidia and Eli Lilly Are Partnering on a $1 Billion Lab. Here's What Investors Need to Know. - The Motley Fool
NVIDIA and Lilly launch $1B AI lab for drug discovery ... - eeNews Europe
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $1,265 - 富途资讯
Rakuten Securities Inc. Boosts Stock Position in Eli Lilly and Company $LLY - MarketBeat
OVERSEA CHINESE BANKING Corp Ltd Has $15.61 Million Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
NVIDIA and Eli Lilly Launch AI Co-Innovation Lab for Drug Development - HLTH
Eli Lilly stock slides premarket after FDA sets April 10 target for weight-loss pill decision, GLP-1 lawsuit filed - TechStock²
Forbes J M & Co. LLP Acquires 3,186 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Holdings Reduced by Fjarde AP Fonden Fourth Swedish National Pension Fund - MarketBeat
Blalock Williams LLC Buys New Position in Eli Lilly and Company $LLY - MarketBeat
[JPM 2026] ABL Bio seeks next license-out after GSK, Eli Lilly deals - theinvestor.co.kr
Regulatory Hurdles and Legal Challenge Weigh on Eli Lilly Shares - AD HOC NEWS
Eli Lilly stock slides after FDA pushes obesity pill decision to April 10 - TechStock²
Lobbying Update: $2,200,000 of ELI LILLY AND COMPANY lobbying was just disclosed - Quiver Quantitative
IU and Eli Lilly team up to study impact of GLP-1 drugs in workplace - WRTV
Eli Lilly and Novo Nordisk Accused of Blocking Access to Lower-Cost Weight-Loss Drugs - PYMNTS.com
Eli Lilly Stock Slips After Antitrust Lawsuit Against GLP-1 Providers - Benzinga
Why Eli Lilly (LLY) Stock Is Down Today - Finviz
Eli Lilly (LLY) Faces Potential Delay in Weight Loss Pill Approval - GuruFocus
Disc Medicine, Sanofi, Eli Lilly Shares Slip On Reports Of FDA Increasing Review Time For Drugs Granted Priority Review Vouchers - Stocktwits
Eli Lilly drops as FDA decision on weight loss pill is now expected in April - Seeking Alpha
JPM: NVIDIA and Eli Lilly announce co-innovation AI lab - MobiHealthNews
Where is Eli Lilly and Company (LLY) Headed According to Analysts? - Insider Monkey
0.21%
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):